As several types of immune effector cells within the tumor microenvironment express the cognate receptors for C3a and C5a, investigators have postulated that intratumoral elaboration of anaphylatoxins drives local immunosuppression and at least partially accounts for the newly recognized cancer-promoting role of complement activation 1,3–5. The gene discussed is C5; the disease is cancer.